APITBIO is a South Korean biotech company dedicated to the research and development of antibody-based innovative immuno-oncology therapeutics focusing on novel targets. It was established by a group of highly distinguished experts in the field of antibody development and the target, L1CAM (CD171) with the cooperation consisting of academia, industries, research institutes, and hospitals in order to fight the cancer and meet the unmet medical needs of patients.
Partnership through open innovations is one of the top priorities for us. Based on our antibody-based innovative therapeutic development platforms and outstanding R&D workforce to recognize and optimize precision medicine, APITBIO strives to grow into a world-class biotech company that develops antibody-based and innovative platform-based therapeutics through partnerships and open innovation with domestic and overseas networks.
Partnership through open innovations is one of the top priorities for us. Based on our antibody-based innovative therapeutic development platforms and outstanding R&D workforce to recognize and optimize precision medicine, APITBIO strives to grow into a world-class biotech company that develops antibody-based and innovative platform-based therapeutics through partnerships and open innovation with domestic and overseas networks.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2018
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Ab612, FIC mAb targeting L1CAM (CD171)
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
